The marked responses observed in Pc1Pik3cap110* pancreatic cancers indicate great promise for the use of agents targeting the PI3K cascade, such as dual PI3K/mTOR inhibitors. The gene discussed is MTOR; the disease is familial pancreatic carcinoma.